title: [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
abstract: Objective:From the perspective of health economics, to evaluate 23 pneumococcal polysaccharide vaccination programme among chronic obstructive pulmonary disease (COPD) patient.Methods:In the pilot counties of the project of integrated care pathway for COPD patient (Hanbin district of Hanzhong city in Shanxi Province, Qianjian district of Qingqing city, Huandao district of Qindao city in Shangdong Province, Wen county of Jiaozuo city in Henan Province), information of insurance participants of New Rural Cooperative Medical System (NRCS) was collected by local NRCM information system, which included general information as well as records of medical care and medical fee. Nonprobability sampling method was applied to select a total of 860 objects, who were over 60 years old with local household registration, hospitalized within one recent year due to COPD acute exacerbation, and without vaccination of 23 voluntary pneumococcal polysaccharide vaccine within 3 years. A quasi-experimental design without control group was adopted. Objects were vaccinated with 23-valent pneumococcal polysaccharide vaccine from January to December in 2013, then were followed up from January in 2014 for one year. Data of effectiveness and medical cost was collected by self-designed questionnaire and <EuroQol five dimensions questionnaire >(Chinese version). Paired rank sum test applied to test the difference of quality of life, number and direct medical cost of treatment (including outpatient treatment and hospitalization) due to COPD acute exacerbation, one year before and after intervention. The incremental cost-effectiveness ratio (ICER) and cost-benefit ratio (CBR) of the programme were calculated.Results:By January 2014, eight hundred sixty objects were vaccinated. By January 2015, seven hundred eighty eight objects were followed up, with 72 cases withdrawed (8.4%). On average, COPD patients reduced 1.12±2.51 treatments due to acute exacerbation, including 0.28±2.09 outpatient treatments and 0.85±1.15 hospitalizations. Total medical cost was saved by 3 610.21 per capita yuan, including outpatient cost of 241.41 yuan and hospitalization cost of 269.82 yuan; Quality of life was gained by 0.03 QALY gain per capita. The ICER was dominant and CBR was 12.00.Conclusion:COPD patients vaccinated with 23-valent pneumococcal polysaccharide vaccine within one year reduced treatments due to acute exacerbation. The vaccination was cost effective and cost saving , and we suggest the vaccine should be covered in the public health program or health insurance scheme in conditional region.
authors.affiliation: National Health Development Research Center, Beijing 100191, China.
authors.forename: Y P
authors.initials: YP
authors.lastname: Qiu
authors.forename: K
authors.initials: K
authors.lastname: Zhao
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: L W
authors.initials: LW
authors.lastname: Shi
authors.forename: W D
authors.initials: WD
authors.lastname: Guo
authors.forename: X R
authors.initials: XR
authors.lastname: Qi
authors.forename: B Y
authors.initials: BY
authors.lastname: Sui
authors.forename: R M
authors.initials: RM
authors.lastname: Zhou
mesh_terms: D000368:Aged; D002681:China / Q000453:epidemiology; D003362:Cost-Benefit Analysis / Q000379:methods*; D017048:Health Care Costs; D006760:Hospitalization; D006801:Humans; D007114:Immunization / Q000191:economics*; D017589:Immunization Programs / Q000191:economics*; D010865:Pilot Projects; D022242:Pneumococcal Vaccines / Q000191:economics*; D015397:Program Evaluation; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D014611:Vaccination / Q000191:economics*
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines